Pharmacogenetics (PGx) -- the analysis of how genes affect a person’s ability to receive the therapeutic benefit intended from prescription medications

When we consider the knowledge and resources we have available to us today, continuing to provide healthcare coverage that does not include PGx testing is like investing money in a stock that is doomed to fail because you don’t know the true inner workings of that company – 

While being able to predict the future return on a stock may not be a predictable science, using PGx testing and our genes to predict future health outcomes related to drug compatibility is.  

Consider these actual case examples and the potential impact of PGx testing:

ChromoCare™ is a precision medicine company dedicated to improving health outcomes and reducing healthcare costs with its innovative approach to patient drug-compatibility testing and addiction prevention through DNA analysis. Our approach eliminates typical Trial-and-Error medication prescribing and stems the rising pharmacy cost for patients and employers.

Employer groups are ChromoCare’s primary target market.  

ChromoCare’s The G.A.P Test™ enables physicians to prescribe to their patients the right drug treatment and dosage the first time-- effectively reducing Trial-and-Error medication prescribing.

The G.A.P Test decreases adverse drug reaction, lowering pharmacy prescription and overall healthcare costs. This significantly improves patient health outcomes by getting them on the right medication, the first time..  

Additionally, ChromoCare’s proprietary ChromALERT™ test determines an individual’s genetic susceptibility to opiate addiction. ChromALERT™ also gives the physician and the patient insight into their potential risk of addiction and thereby allow for making more informed decisions before prescribing opiates for treatment.

Prescription medications are a necessity to countless patients, some 290 Million
in the US that are currently under a medication prescription through their physician.

But when given the wrong treatment or wrong dosage for their ailment, it can lead to serious consequences; the medication being ineffective in giving relief, causing negative reactions with other drugs the patient is taking, or causing Adverse Drug Reactions (ADRs). 

As a result of trial-and-error prescribing -- the norm in primary healthcare -- patients often have to return many times to their doctor to have their prescription revised.

Simply put, trial-and-error prescribing is a significant waste of medicine, money, and time -- on top of the devastating impact it can have on patients.

It is not inevitable, it is avoidable - and ChromoCare is leading the way.  

The principal issues with current PGx testing are in these areas:

A relatively new field of study has emerged with the potential to enable physicians to prescribe the right dosage of the right medication for the right indication at the right time -- effectively improving treatment outcomes, decreasing the incidence of ADRs, and ultimately reducing the cost of pharmacy and overall healthcare. 

PGx testing starts with a simple cheek swab to collect the patient’s DNA. That swab is  processed and analyzed in a high-complexity, state of the art laboratory to yield the test results that give the patient and their physician a report about how the patient will respond to a particular medication. The G.A.P Test, unlike competitors, makes a recommendation on a drug and dosage more appropriate for the physician to prescribe to the patient that will provide relief without negative interaction consequences.

While PGx testing represents an effective and promising breakthrough in modern medication prescribing, it’s also not without challenges.  

The G.A.P Test™, (Genetic Assisted Prescribing), is the most comprehensive drug compatibility test on the market, allowing physicians to access their patient’s genetic profile to confidently prescribe the right drug and the right dosage, the first time. 

Easy To Understand
Simple emojis are used to deliver the scientific gene-drug recommendations in a way that both the physician and patient can easily understand, which encourages the physician to take action and make prescription decisions based on sound science. 

Validated Genetic Information
Gene-drug recommendations are based on thousands of clinical studies validated by CPIC -- the international consortium of leading health systems (Mayo, Cleveland Clinic, Stanford University, St. Jude’s, Johns Hopkins, University of Texas, MD Anderson, etc). ChromoCare is the only PGx testing company that uses CPIC validations exclusively. 

Cost-Effective
By exploding the cost structure of a typical PGx provider, ChromoCare is able to provide a lower-cost alternative, while providing a superior product.  

Genes & Medications
Covers 20+ genes, 350+ medications, and 12 therapeutic categories, including: Anxiety/Depression, Pain Management, Oncology, Birth Control, Neurology, Gastroenterology, Cardiovascular, Endocrinology, Infectious Disease, Psychiatry/Antipsychotic, Rheumatology and Hematology.

Faster Turnaround
Patients receive ChromoCare’s PGx testing with 5-7 day turnaround times.

ChromLab Network
Rather than deploying major capital expenditures to build and operate laboratories, we formed a proprietary ChromoCare network of independent CLIA-approved clinical laboratories.  CLIA is the US Government’s certification of laboratories meeting federal guidelines. This allows us to eliminate unnecessary costs to create a financially successful business model while providing better health outcomes in the US.

More Affordable
At less than $800 per test, ChromoCare offers competitive pricing.

D N A  S A M P L I N G
The patient’s DNA is collected with a simple non-invasive cheek swab and sent to a predetermined ChromoCare laboratory. The bar code trackingof the test kit allows the sample to be sent to the nearest lab in the ChromLab Network, shortening the turnaround time.  These logistics are significantly automated through ChromTrak, ChromoCare’s proprietary order management and fulfillment system.

T E S T I N G
Once in the lab, the sample is handled under strict laboratory guidelines and entered into ChromoCare’s proprietary assay. The DNA sample is tested against our CPIC validated guidelines, which compares it to new and existing prescriptions.

R E S U L T S
Test results typically take 5 days. The test report informs the physician as to which medication will best metabolize for that patient’s particular ailment, potential interactions with other drugs being taken, and the risk of ADRs. In many cases it is found that analysis between drugs being taken by the patient can significantly reduce the number of drugs being taken in those patients taking more than one drug. 

ChromoCare’s most notable accomplishments and milestones to date include:  

ChromoCare’s leadership is made up of a team of seasoned industry veterans united under a common vision to advance the practice of precision medicine by making personalized care available to healthcare providers everywhere.

HUGH CATHEY | CHAIRMAN & CEO
Hugh has been an investor and CEO of both public and private tech companies and has achieved multiple successful IPOs and exits. ChromoCare is Hugh’s 9th startup. 

JEFF GARSHON | FOUNDER, PRESIDENT
& BOARD MEMBER
Jeff co-developed The G.A.P Test with our scientific team and has broad expertise in healthcare marketing.  He is particularly focused on marketing to TPA’s, health plans and big pharma. 

JODIE FORTINE | COO
Jodie has significant operations and logistics experience in financial, education, and healthcare companies with prior entrepreneurial experience leading her own healthcare/sports management company. 

MIKE SAYRE | CFO
Mike has achieved multiple tech company exits as CEO/COO/CFO.